426 related articles for article (PubMed ID: 18775859)
1. Nona-D-arginine therapy for Pseudomonas aeruginosa keratitis.
Karicherla P; Hobden JA
Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):256-62. PubMed ID: 18775859
[TBL] [Abstract][Full Text] [Related]
2. Nona-D-arginine amide for prophylaxis and treatment of experimental Pseudomonas aeruginosa keratitis.
Karicherla P; Hobden JA
Curr Eye Res; 2010 Mar; 35(3):220-4. PubMed ID: 20373880
[TBL] [Abstract][Full Text] [Related]
3. Nona-D-arginine amide suppresses corneal cytokines in Pseudomonas aeruginosa keratitis.
Karicherla P; Aras S; Aiyar A; Hobden JA
Cornea; 2010 Nov; 29(11):1308-14. PubMed ID: 20802321
[TBL] [Abstract][Full Text] [Related]
4. Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.
Sanders ME; Moore QC; Norcross EW; Sanfilippo CM; Hesje CK; Shafiee A; Marquart ME
Cornea; 2011 Jan; 30(1):83-90. PubMed ID: 20847656
[TBL] [Abstract][Full Text] [Related]
5. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of experimental Pseudomonas aeruginosa keratitis.
Guzek JP; Chacko D; Kettering JD; Wessels IF; Aprecio RM
Cornea; 1994 Nov; 13(6):500-4. PubMed ID: 7842708
[TBL] [Abstract][Full Text] [Related]
6. Keratotomy model of pseudomonas keratitis: gentamicin chemotherapy.
Brockman EB; Tarantino PA; Hobden JA; Hill JM; O'Callaghan RJ; Kaufman HE; Insler MS
Refract Corneal Surg; 1992; 8(1):39-43. PubMed ID: 1554638
[TBL] [Abstract][Full Text] [Related]
7. Spantide I decreases type I cytokines, enhances IL-10, and reduces corneal perforation in susceptible mice after Pseudomonas aeruginosa infection.
Hazlett LD; McClellan SA; Barrett RP; Liu J; Zhang Y; Lighvani S
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):797-807. PubMed ID: 17251480
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
Caballero AR; Marquart ME; O'Callaghan RJ; Thibodeaux BA; Johnston KH; Dajcs JJ
Curr Eye Res; 2006 Jan; 31(1):23-9. PubMed ID: 16421016
[TBL] [Abstract][Full Text] [Related]
9. Role of IL-12 and IFN-gamma in Pseudomonas aeruginosa corneal infection.
Hazlett LD; Rudner XL; McClellan SA; Barrett RP; Lighvani S
Invest Ophthalmol Vis Sci; 2002 Feb; 43(2):419-24. PubMed ID: 11818386
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model.
Oguz H; Ozbilge H; Oguz E; Gurkan T
Curr Eye Res; 2005 Mar; 30(3):155-61. PubMed ID: 15804740
[TBL] [Abstract][Full Text] [Related]
11. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.
Rhee MK; Kowalski RP; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
Am J Ophthalmol; 2004 Aug; 138(2):226-30. PubMed ID: 15289131
[TBL] [Abstract][Full Text] [Related]
12. Povidone-iodine (betadine) in the treatment of experimental Pseudomonas aeruginosa keratitis.
Michalová K; Moyes AL; Cameron S; Juni BA; Obritsch WF; Dvorak JA; Doughman DJ; Rhame FS
Cornea; 1996 Sep; 15(5):533-6. PubMed ID: 8862931
[TBL] [Abstract][Full Text] [Related]
13. Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits.
Jensen H; Zerouala C; Carrier M; Short B
J Ocul Pharmacol Ther; 2005 Feb; 21(1):36-43. PubMed ID: 15718826
[TBL] [Abstract][Full Text] [Related]
14. Effect of propolis in the treatment of experimental Staphylococcus aureus keratitis in rabbits.
Oksuz H; Duran N; Tamer C; Cetin M; Silici S
Ophthalmic Res; 2005; 37(6):328-34. PubMed ID: 16138004
[TBL] [Abstract][Full Text] [Related]
15. Treatment of experimental bacterial keratitis with topical trovafloxacin.
Barequet IS; Denton P; Osterhout GJ; Tuli S; O'Brien TP
Arch Ophthalmol; 2004 Jan; 122(1):65-9. PubMed ID: 14718297
[TBL] [Abstract][Full Text] [Related]
16. Quinolones in collagen shields to treat aminoglycoside-resistant pseudomonal keratitis.
Hobden JA; Reidy JJ; O'Callaghan RJ; Insler MS; Hill JM
Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2241-3. PubMed ID: 2173684
[TBL] [Abstract][Full Text] [Related]
17. Effect of systemic tetracycline on progression of Pseudomonas aeruginosa keratitis in the rabbit.
Levy JH; Katz HR
Ann Ophthalmol; 1990 May; 22(5):179-83. PubMed ID: 2114813
[TBL] [Abstract][Full Text] [Related]
18. Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model.
Mah FS; Romanowski EG; Kowalski RP; Yates KA; Gordon YJ
Cornea; 2007 Jun; 26(5):585-8. PubMed ID: 17525656
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of a new tobramycin (0.3%) and dexamethasone (0.05%) formulation in the treatment of experimental Pseudomonas keratitis.
McCormick C; Caballero A; Tang A; Balzli C; Song J; O'Callaghan R
Curr Med Res Opin; 2008 Jun; 24(6):1569-75. PubMed ID: 18423106
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis.
Engel LS; Callegan MC; Hill JM; Folkens AT; Shimomura Y; O'Callaghan RJ
Jpn J Ophthalmol; 1996; 40(2):212-9. PubMed ID: 8876389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
